PDCD1 and urinary bladder cancer: In summary, the first domestically approved ADC (disitamab vedotin) combined with PD-1 inhibitors (tislelizumab and toripalimab) demonstrates a higher pathological complete response rate and pathological downstaging rate in the neoadjuvant treatment of bladder cancer than traditional GC chemotherapy.